Retatrutide 3D 20mg UAE: Pre-Filled Pen & Product Guide

Retatrutide 3D 20mg UAE is a product listing featuring a pre-filled pen labeled 20mg/3ml, with the packaging stating that one pen contains 5 doses. The box also carries the wording “For export only,” while the pen is labeled as a 20mg/3ml solution.

Retatrutide itself is an investigational compound also known as LY3437943. It is being studied as a triple receptor agonist involving the GIP, GLP-1 and glucagon pathways. Current clinical development has progressed into Phase 3 and Phase 3b studies, but retatrutide has not been approved for public use.

For UAE readers, the distinction between an online product listing and an authorized pharmaceutical medicine is especially important. The product packaging and online availability should therefore be considered separately from regulatory authorization.

Quick Product Overview

Product Information

Details

Product

Retatrutide 3D

Active compound

Retatrutide

Development code

LY3437943

Listed strength

20mg

Listed volume

3ml

Format

Pre-filled pen

Packaging statement

1 pen contains 5 doses

Labeling

For export only

Pen labeling

20mg/3ml solution

Scientific category

Investigational compound

Market context

UAE / export-oriented listing

The product-specific details in this table are based on the supplied packaging image. Current batch, manufacturer, COA, storage and regulatory documentation should be verified separately.

What Is Retatrutide?

Retatrutide is an investigational molecule developed by Eli Lilly and identified in scientific and clinical-trial records by the code LY3437943.

Its main scientific distinction is its activity across three receptor pathways:

• GLP-1
• GIP
• Glucagon

Because it interacts with all three, retatrutide is commonly described as a triple agonist. This distinguishes it mechanistically from single-pathway and dual-pathway metabolic therapies.

Understanding the 20mg/3ml Pen

The supplied packaging identifies this presentation as:

20mg / 3ml

and states:

1 pen contains 5 doses

The pen itself is labeled as a 20mg/3ml solution.

These statements describe the product's packaging and format. They should not be interpreted as a recommendation for how the product should be administered.

Different retatrutide listings can vary in strength, volume, pen design and documentation. Current UAE-focused supplier pages, for example, list pen presentations ranging from 10mg through 60mg.

Retatrutide and the Triple-Receptor Concept

The scientific interest in retatrutide is closely related to its multi-receptor design.

GLP-1 Pathway

GLP-1 signaling is associated with appetite regulation, satiety and glucose-related physiological processes.

GIP Pathway

GIP participates in glucose-dependent signaling and metabolic physiology.

Glucagon Pathway

Glucagon contributes to energy metabolism and regulation of stored energy.

Researchers are investigating whether activity across these three pathways can produce useful metabolic effects in controlled clinical studies.

The mechanism is a description of the investigational compound; it does not establish a particular outcome for an individual product.

Retatrutide Clinical Development

Retatrutide has progressed into a large clinical-development program.

Current clinical studies include Phase 3 and Phase 3b investigations involving obesity and related metabolic conditions. ClinicalTrials.gov records include studies evaluating weight reduction, maintenance of weight reduction, safety, dose-escalation strategies and comparisons with other therapies.

This later-stage development is an important milestone, but clinical-trial progress should not be confused with regulatory approval.

Retatrutide 3D 20mg UAE and Weight-Management Studies

Weight reduction is one of the main areas being investigated in retatrutide clinical development.

Earlier Phase 2 research reported substantial average body-weight changes over 48 weeks, while later Phase 3 programs have evaluated longer follow-up and different patient populations.

When reading weight-related clinical findings, it is important to consider:

• Study population
• Duration
• Comparator
• Studied dose
• Primary endpoints
• Safety findings

Group-level clinical results do not guarantee a particular outcome for an individual.

 Retatrutide 3D 20mg UAE Product Presentation

The Retatrutide 3D 20mg UAE packaging supplied for this page shows a clean pre-filled pen presentation with:

RETATRUTIDE 3D

20mg/3ml

1 pen contains 5 doses

The package also includes the statement:

For export only

These visible identifiers can be useful for product cataloging and differentiation from other strengths.

At the same time, packaging text does not by itself establish authenticity, purity, sterility, clinical effectiveness or regulatory authorization.

Why Exact Product Identification Matters

Retatrutide products can be offered in different forms and strengths.

Current UAE-facing research listings show multiple pen and vial options, including 20mg, 30mg, 40mg, 50mg and 60mg presentations.

For that reason, a product page should clearly distinguish:

Strength

Verify the stated milligram amount.

Volume

Check the listed total volume.

Format

Identify whether the presentation is a pen or vial.

Batch

Look for a lot or batch reference.

Documentation

Review any available COA or laboratory records.

Intended use

Confirm the product's declared research or regulatory category.

Product Verification and Laboratory Documentation

For investigational compounds, documentation can be as important as the product name.

Certificate of Analysis

A batch-specific COA can connect analytical findings to a specific lot.

Purity Testing

Some UAE research suppliers publish HPLC-based purity information or independent testing records.

Identity Testing

Laboratory methods can provide evidence about the identity of the material.

Batch Traceability

A unique batch number can make documentation easier to verify.

Supplier Information

The supplier or manufacturer should be clearly identified where applicable.

A documentation package does not itself establish approval for human use, but it can improve transparency and traceability.

Retatrutide 3D 20mg UAE and Regulatory Considerations

The UAE regulatory position should be clearly separated from product marketing.

The Abu Dhabi Department of Health issued Circular No. 40/2026 on March 6, 2026, warning healthcare facilities, professionals and the public against unauthorized retatrutide products. The circular states that retatrutide remained under clinical development and that unauthorized products were not licensed or authorized for use or distribution.

This is especially relevant when evaluating online product pages.

Important distinction

Online listing ≠ regulatory approval

Clinical development ≠ public authorization

Packaging label ≠ proof of authenticity

Listed price ≠ official medicine price

A professional product page should avoid implying otherwise.

How to Evaluate a Retatrutide Pen

Before relying on a product listing, check:

Product name and strength

Confirm that the label matches the listing.

Volume

Verify the total stated volume.

Batch details

Look for lot identification.

Testing documents

Review available laboratory and COA information.

Supplier identity

Confirm who is responsible for the product.

Current UAE status

Check official UAE health-authority information rather than relying solely on seller claims.

Frequently Asked Questions

What is Retatrutide 3D 20mg UAE?

It is a product presentation labeled RETATRUTIDE 3D 20mg/3ml and shown in the supplied image as a pre-filled pen.

How much does the package contain?

The supplied packaging states 20mg/3ml.

How many doses does one pen contain?

The box states that 1 pen contains 5 doses.

What is LY3437943?

LY3437943 is the development code associated with retatrutide.

Why is retatrutide called a triple agonist?

Because it is being investigated across GIP, GLP-1 and glucagon receptor pathways.

Is retatrutide approved in the UAE?

The Abu Dhabi Department of Health issued a March 2026 warning describing retatrutide as an unauthorized medical product and stating that it remained under clinical development.

Does the packaging prove product authenticity?

No. Packaging alone does not establish authenticity, purity, sterility, safety or regulatory authorization.

What should be checked before evaluating the product?

Check the exact label, strength, volume, batch information, laboratory documents, COA and current regulatory status.

Conclusion

Retatrutide 3D 20mg UAE is a pre-filled pen presentation identified on the supplied packaging as 20mg/3ml, with the package stating that one pen contains five doses.

Retatrutide itself is an investigational triple receptor agonist involving GIP, GLP-1 and glucagon pathways and is currently being evaluated through a broad clinical-development program.

For UAE readers, regulatory context is particularly important. The Abu Dhabi Department of Health has warned against unauthorized retatrutide products and stated that the compound remains under clinical development.

A well-structured product page should therefore provide accurate identification, clear specifications, transparent documentation and appropriate regulatory language.

Research & Regulatory Disclaimer

This page is provided for educational and product-identification purposes only. It does not provide individualized medical advice, dosing instructions, injection protocols or treatment recommendations.

Retatrutide remains investigational and is not currently approved for public use. Online availability does not establish regulatory authorization, authenticity, purity, safety or suitability for personal treatment. Always verify current UAE regulatory information and official product documentation.